Is teicoplanin available in the United States?

No. Teicoplanin is not FDA-approved in the US. It is approved and widely used in Europe, the UK, and many Asian and other countries.

What infections does teicoplanin treat?

Serious Gram-positive infections, including MRSA-related bacteremia, endocarditis, bone and joint infections, and complicated skin/soft-tissue infections.

Is teicoplanin safer than vancomycin?

Comparative studies and meta-analyses consistently report similar efficacy with fewer adverse events - notably less nephrotoxicity and red-man syndrome - though it still requires medical supervision and adequate dosing/monitoring.

Does teicoplanin need blood-level monitoring?

Increasingly, yes. Because exposure varies and underdosing can reduce efficacy, therapeutic drug monitoring is recommended especially in critically ill patients and deep-seated infections such as endocarditis and bone infection.

EMA-approvedaka Targocid

Teicoplanin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Teicoplanin (also known as Targocid) is a peptide catalogued under Cyclic & Antimicrobial (Glycopeptide antibiotic). It is described as: D-Ala-D-Ala. Documented context: Gram-positive infections. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Teicoplanin?

Teicoplanin is a glycopeptide antibiotic - structurally related to vancomycin - used to treat serious Gram-positive infections including those caused by MRSA, such as bacteremia, endocarditis, bone and joint, skin/soft-tissue and complicated infections.

It is approved and widely used in Europe, the United Kingdom, and many Asian and other countries, but it is NOT FDA-approved in the United States; it is a hospital prescription drug, not a supplement.

Evidence is human and clinical, including randomized trials, Cochrane and other systematic reviews/meta-analyses, and pharmacokinetic studies; it is generally reported to have renal tolerability at least comparable to, and often better than, vancomycin.

How does Teicoplanin work?

Like vancomycin, teicoplanin binds the D-alanyl-D-alanine terminus of cell-wall peptidoglycan precursors, inhibiting bacterial cell-wall synthesis in Gram-positive organisms.

Its long elimination half-life allows once-daily and eventually less-frequent dosing after loading, and it can be given intramuscularly as well as intravenously.

What does the research say about Teicoplanin?

Teicoplanin shows efficacy broadly comparable to vancomycin for Gram-positive infections while being associated with fewer adverse events, particularly less nephrotoxicity, in pooled analyses. ^[1]
A Cochrane systematic review of randomized trials found similar clinical cure rates to vancomycin but a lower risk of nephrotoxicity and red-man syndrome. ^[2]
Its long half-life supports convenient once-daily (and outpatient) dosing after a loading regimen, though therapeutic drug monitoring helps achieve adequate exposure. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis — Svetitsky S et al., Antimicrobial Agents and Chemotherapy 2009. (Systematic review and meta-analysis)
[2] Teicoplanin versus vancomycin for proven or suspected infection — Cavalcanti AB et al., Cochrane Database of Systematic Reviews 2010. (Cochrane systematic review of RCTs)
[3] Clinical pharmacokinetics of teicoplanin — Wilson AP et al., Clinical Pharmacokinetics 2000. (Pharmacokinetic review)
[4] Pharmacokinetics and Target Attainment of Teicoplanin: A Systematic Review — Mouton JWA et al., Clinical Pharmacokinetics 2025. (Systematic review)
[5] Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection — Bugano DD et al., Einstein (Sao Paulo) 2011. (Systematic review/meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: teicoplanin is administered intravenously (or intramuscularly) in hospital, typically with several loading doses followed by once-daily maintenance individualized to the infection site and renal function.

Dosing and therapeutic drug monitoring are managed by clinicians and pharmacists; nothing here is dosing guidance and it is not self-administered.

Side effects & safety profile

Teicoplanin is generally well tolerated, and multiple comparative studies report a lower incidence of nephrotoxicity and infusion-related (red-man) reactions than vancomycin.

Reported adverse effects include hypersensitivity/rash, injection-site reactions, thrombocytopenia (more likely at higher doses), and occasional hepatic enzyme elevations; underdosing is a practical risk because adequate loading and monitoring are needed for efficacy.

It must be used under medical supervision; therapeutic drug monitoring is increasingly recommended, especially in critically ill, obese, renally impaired, or deep-seated infections such as endocarditis and osteoarticular disease.

Stacking & combinations

In severe infections it may be combined with agents such as rifampin or an aminoglycoside under specialist direction, a decision left to the treating team.

Finding Teicoplanin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

No, but they are closely related glycopeptide antibiotics with the same basic cell-wall mechanism. Teicoplanin has a longer half-life allowing once-daily dosing, can be given intramuscularly, and tends to cause less nephrotoxicity and fewer infusion reactions.

References

[1] Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis — Svetitsky S et al., Antimicrobial Agents and Chemotherapy 2009. PMID: 19596875. View sourceStudy: Systematic review and meta-analysisTeicoplanin had similar efficacy to vancomycin but significantly fewer adverse events, including less nephrotoxicity.
[2] Teicoplanin versus vancomycin for proven or suspected infection — Cavalcanti AB et al., Cochrane Database of Systematic Reviews 2010. PMID: 20556772. View sourceStudy: Cochrane systematic review of RCTsComparable clinical cure rates with lower risk of nephrotoxicity and red-man syndrome for teicoplanin.
[3] Clinical pharmacokinetics of teicoplanin — Wilson AP et al., Clinical Pharmacokinetics 2000. PMID: 11020133. View sourceStudy: Pharmacokinetic reviewCharacterizes teicoplanin's long half-life, protein binding and the loading/monitoring needed for adequate exposure.
[4] Pharmacokinetics and Target Attainment of Teicoplanin: A Systematic Review — Mouton JWA et al., Clinical Pharmacokinetics 2025. PMID: 40064832. View sourceStudy: Systematic reviewHighlights variable pharmacokinetics and frequent underexposure, supporting therapeutic drug monitoring to hit efficacy targets.
[5] Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection — Bugano DD et al., Einstein (Sao Paulo) 2011. PMID: 26761092. View sourceStudy: Systematic review/meta-analysisConfirms similar efficacy to vancomycin with a more favorable adverse-event profile for teicoplanin.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.